Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342

Table 4 Objective response rates by clinical characteristics, HER2 status, and p53 status

Variable	Number of patients^a	Response rate (%)	P value^b
Age			0.045
>50 years	108	29
≤50 years	50	14
Performance status			0.81
0	77	23
1 or 2	80	25
ER			0.056
Positive	70	17
Negative	71	31
PR			0.51
Positive	64	22
Negative	71	27
ER/PR			0.22
At least 1 positive	81	20
Both negative	59	29
Number of metastatic sites			0.50
0–2	139	25
>2	17	18
Disease-free interval			0.10
≤2 years	101	20
>2 years	57	32
Prior adjuvant chemotherapy			0.83
Yes	94	24
No	61	23
HER2 CBll			0.96
Positive	30	23
Negative	126	24
HER2 FISH			0.70
Positive	37	22
Negative	109	25
HER2 HercepTest			0.026
Positive: 2–3	46	35
Negative: 0–1	105	18
HER2 HercepTest			0.98
Positive: 3	30	23
Negative: 0–2	121	23
p53 IHC			0.79
Positive	56	23
Negative	89	21
p53 Mutation			0.55
Present	42	21
Absent	103	26

^aNot all patients could be evaluated for a response, and those who could not be evaluated have been excluded. ^b P values are for comparisons of the proportion of patients with a response to paclitaxel in each group. ER, estrogen receptor; FISH, fluorescent in situ hybridization; IHC, immunohistochemistry; PR, progesterone receptor.

ISSN: 1465-542X